Compare DexCom, Inc. (DXCM) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs McCormick & Company, Incorporated — how do they compare? DexCom, Inc. trades at $85.15 (market cap $31.86B), while McCormick & Company, Incorporated trades at $45.5 (market cap $12.39B). The key difference: DexCom, Inc. is far larger — about 2.6× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays a 4.18% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and McCormick & Company, Incorporated for 67 Days on average.
| DXCM | MKC | |
|---|---|---|
Market Cap | $31.86B | $12.39B |
Volume | 3,607,070 | 6,140,872 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $71.65 |
52-Week Low | $54.84 | $44.14 |
Typical Hold Time | 62 Days | 67 Days |
Enterprise Value | $31.32B | $17.07B |
Dividend Yield | — | 4.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
MKC trades at $45.25, down 0.33% on the day, with a bearish technical signal but attractive valuation metrics including a P/E of 8.31. The company reported strong Q3 2026 earnings of $0.86 per share, beating estimates, driven by 17% sales growth and margin expansion. Recent dividend declaration of $0.48 per share provides income support. Revenue growth has been steady, reaching $6.84B in 2025 with net income of $789.4M.
The stock presents value opportunity with below-sector P/E ratio and consistent profitability (19.39% net margin), though technical indicators signal near-term weakness. Analyst consensus is mixed with 33% buy ratings but $53.50 price target suggests 18% upside. Key risks include integration challenges from acquisitions and consumer spending sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
